treatment

“We fight two battles to control lung cancer”

Posted by  | treatment

Medical teams at the Johns Hopkins Kimmel Cancer Center on the Johns Hopkins Bayview campus “have to fight two battles in order to control the cancer,” says radiation oncologist says Russell K. Hales, M.D. “The first is the local disease. A lung tumor is problematic, because as it grows, it can cause shortness of breath,(...)

Why is lung cancer so difficult to treat?

Posted by  | treatment

“When we think about lung cancer, we usually think of it being associated with people who smoke,” says Russell K. Hales, M.D. “But, in fact, non-smoking associated lung cancer is common as well”.  In fact, if non-smoking associated lung cancer were its own category, it would rank in the top ten for cancer related death(...)

Our Story of Cancer: Alleviate the Suffering of Patients with Cancer

Posted by  | treatment

We've asked our staff to share their thoughts on the PBS documentary, Cancer: Emperor of All Maladies. This week, we'll post their comments, including how they hope it will influence the public dialogue on cancer, research and treatment. Ephraim Fuchs, M.D., M.B.A., professor of oncology and immunology at the Johns Hopkins Kimmel Cancer Center shares his thoughts:(...)

Our Story of Cancer: Further Gains in Preventing, Treating and Curing Cancer in the Near Future

Posted by  | Prevention/Screening, Research, treatment

We've asked our staff to share their thoughts on the PBS documentary, Cancer: Emperor of All Maladies. This week, we'll post their comments, including how they hope it will influence the public dialogue on cancer, research and treatment. Terry Langbaum, MHS, Chief Administrative Officer at the Johns Hopkins Kimmel Cancer Center, shares her thoughts: We are hoping(...)

Immunotherapy drug approved for lung cancer

Posted by  | treatment

There is good news today for lung cancer patients. The FDA has announced that it has approved expansion of the immunotherapy drug nivolumab (Opdivo) for certain lung cancer patients. Julie Brahmer, M.D., oncologist at the Johns Hopkins Kimmel Cancer Center and director of its Thoracic Oncology Program, is one of the leaders of the initial,(...)